so, did Gerald just pick up a $17,718.75 check tod
Post# of 30028
Quote:
"Filing our second Orphan Drug Designation for MANF is an important component of our regulatory strategy for the program," said Gerald E. Commissiong, President & CEO of Amarantus.
***** 4 Bonus Milestones *****
1.) Nasdaq Uplist
30% Bonus = $35,437.50
2.) Eltoprazine US IND filed & Approved for LID
30% Bonus = $35,437.50
3.) LymPro Partner Validation of APP & CLIA Certification
25% Bonus = $29,531.24
4.) MANF ODD Apps Filed & Approved for OIA & RP
15% Bonus = $17,718.75